Clinical trial · Observational
Establishment of a Tumor Bank for Tissue Samples
Establishment of a Tissue Sample Bank in the Field of Gynaecological Oncology
NCT01789229CI-TRIAL-00064948recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Establishment of a tumor bank, consisting of tissue samples of tumor patients (benign and malign tumors) and healthy people as controls. The tissue samples will be collected systematically together with the corresponding clinical data. The biological samples, the clinical date together with prospective experimental date constitute the entity of the tissue tumor bank. This tumor bank for tissue samples, together with our tumorbank for blood samples (NCT01763125) combined constitute the entity "Tumorbank".
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Neoplasms | Breast Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Colorectal Neoplasms | Colorectal Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Endocrine Gland Neoplasms | — | UNRESOLVED | — |
| Lung Neoplasms | Lung Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Neoplasms of the Female Genitalia | — | UNRESOLVED | — |
| Ovarian Neoplasms | Ovarian Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (7)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Collecting saliva sample | Other | — | UNRESOLVED |
| Collecting sputum | Other | — | UNRESOLVED |
| Collecting stool samples | Other | — | UNRESOLVED |
| Collecting urine samples | Other | — | UNRESOLVED |
| Lavage/Irrigation | Other | — | UNRESOLVED |
| Sampling of ascites and pleural effusion | Other | — | UNRESOLVED |
| Tumor tissue collection | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Malignant tumors
- description
- Patients who have one of the Neoplasms stated above under "conditions".
- interventionNames
- Other: Tumor tissue collection
- Other: Sampling of ascites and pleural effusion
- Other: Collecting urine samples
- Other: Collecting saliva sample
- Other: Collecting sputum
- Other: Collecting stool samples
- Other: Lavage/Irrigation
- label
- Benign controls
- description
- Patients with a benign tumor or an inflammatory disease - to be matched by age.
- interventionNames
- Other: Tumor tissue collection
- Other: Sampling of ascites and pleural effusion
- Other: Collecting urine samples
- Other: Collecting saliva sample
- Other: Collecting sputum
- Other: Collecting stool samples
- Other: Lavage/Irrigation
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Male/Female * Age 18 to 90 years max. * Just one current known malignant disease or just one current inflammatory disease Exclusion Criteria: * Inflammatory disease and malignant disease * multiple malignancies * multiple diseases * underage
References
Publications (5)
- RESULTHofstetter G, Berger A, Fiegl H, Slade N, Zoric A, Holzer B, Schuster E, Mobus VJ, Reimer D, Daxenbichler G, Marth C, Zeimet AG, Concin N, Zeillinger R. Alternative splicing of p53 and p73: the novel p53 splice variant p53delta is an independent prognostic marker in ovarian cancer. Oncogene. 2010 Apr 1;29(13):1997-2004. doi: 10.1038/onc.2009.482. Epub 2010 Jan 18. PMID 20101229
- RESULTTong D, Heinze G, Pils D, Wolf A, Singer CF, Concin N, Hofstetter G, Schiebel I, Rudas M, Zeillinger R. Gene expression of PMP22 is an independent prognostic factor for disease-free and overall survival in breast cancer patients. BMC Cancer. 2010 Dec 15;10:682. doi: 10.1186/1471-2407-10-682. PMID 21159173
- RESULTGrimm C, Watrowski R, Baumuhlner K, Natter C, Tong D, Wolf A, Zeillinger R, Leodolter S, Reinthaller A, Hefler L. Genetic variations of interleukin-1 and -6 genes and risk of cervical intraepithelial neoplasia. Gynecol Oncol. 2011 Jun 1;121(3):537-41. doi: 10.1016/j.ygyno.2011.02.019. Epub 2011 Mar 3. PMID 21376376
- RESULTHofstetter G, Berger A, Schuster E, Wolf A, Hager G, Vergote I, Cadron I, Sehouli J, Braicu EI, Mahner S, Speiser P, Marth C, Zeimet AG, Ulmer H, Zeillinger R, Concin N. Delta133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer. Br J Cancer. 2011 Nov 8;105(10):1593-9. doi: 10.1038/bjc.2011.433. Epub 2011 Oct 18. PMID 22009029
- RESULTPils D, Horak P, Vanhara P, Anees M, Petz M, Alfanz A, Gugerell A, Wittinger M, Gleiss A, Auner V, Tong D, Zeillinger R, Braicu EI, Sehouli J, Krainer M. Methylation status of TUSC3 is a prognostic factor in ovarian cancer. Cancer. 2013 Mar 1;119(5):946-54. doi: 10.1002/cncr.27850. Epub 2012 Oct 23. PMID 23096450